These results help to explain the previous findings that RSK2 gene silencing increases OC cell sensitivity to cisplatin, and RSK inhibition with BI‐D1870 reduces tumor growth and improves survival in xenograft models (van Jaarsveld et al, 2013; Hammoud et al, 2016). Here, RPS6KA3 is linked to neoplasm.